Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administered, selective C5a receptor inhibitor, could replace...

詳細記述

保存先:
書誌詳細
出版年:J Am Soc Nephrol
主要な著者: Jayne, David R.W., Bruchfeld, Annette N., Harper, Lorraine, Schaier, Matthias, Venning, Michael C., Hamilton, Patrick, Burst, Volker, Grundmann, Franziska, Jadoul, Michel, Szombati, István, Tesař, Vladimír, Segelmark, Mårten, Potarca, Antonia, Schall, Thomas J., Bekker, Pirow
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Nephrology 2017
主題:
Clinical Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5576933/
https://ncbi.nlm.nih.gov/pubmed/28400446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016111179
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料